Home › Free Stock Grades › URGN
UroGen Pharma Ltd. (URGN) Stock Grade
URGN · Healthcare
C
Market Cap
$2.0B
P/E Ratio
—
Revenue Growth (YoY)
+21.5%
Net Margin
-139.8%
Return on Equity
145.5%
Dividend Yield
None
About UroGen Pharma Ltd.'s fundamentals
UroGen Pharma is a biotechnology company with a market capitalization of $2.0 billion that has demonstrated strong revenue growth of 21.5% year-over-year, indicating expanding commercial traction. However, the company is currently unprofitable, operating at a net margin of -139.8%, which reflects significant losses on its revenue base. The company does not pay a dividend and lacks a meaningful P/E ratio due to its net loss, which is typical for growth-stage biotechnology firms investing heavily in research, development, and commercialization. Given the company's pre-profitability status, investors should focus on its ability to convert revenue growth into sustainable profitability.